SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q1 2023 vs. Q4 2022
How the institutions holding SAB Biotherapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 38 | 39 | +1 |
| Shares | 4.09M | 3.87M | −223.2K (−5.5%) |
| Value | $2.42M | $1.71M | −$706.1K (−29.2%) |
New holders (7)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| First Manhattan Co | 277,777 | $122.2K | 0.00% |
| Virtu Financial LLC | 15,014 | $7.00K | 0.00% |
| Strategic Financial Concepts, LLC | 15,027 | $6.61K | 0.00% |
| Two Sigma Securities, LLC | 13,439 | $5.91K | 0.00% |
| Gs Investments, Inc. | 2,000 | $880 | 0.00% |
| Harbour Investments, Inc. | 500 | $220 | 0.00% |
| Barclays PLC | 54 | $24 | 0.00% |
Sold out (6)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Shaolin Capital Management LLC | 236,621 | $140.0K |
| AE Wealth Management LLC | 18,700 | $11.0K |
| Susquehanna International Group, LLP | 11,441 | $6.75K |
| Money Concepts Capital Corp | 250 | $147 |
| Bank of America Corp | 38 | $22 |
| Rockefeller Capital Management L.P. | 1,500 | $0 |